Compare Johnson & Johnson (JNJ) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Lockheed Martin Corporation — how do they compare? Johnson & Johnson trades at $261.05 (market cap $626.09B), while Lockheed Martin Corporation trades at $598.75 (market cap $137.96B). The key difference: Johnson & Johnson is far larger — about 4.5× Lockheed Martin Corporation's market cap, and Lockheed Martin Corporation pays the higher dividend (2.31%). Which is the better fit depends on your goals.
| JNJ | LMT | |
|---|---|---|
Market Cap | $626.09B | $137.96B |
Volume | 6,156,228 | — |
Sector | Health | Industrials |
52-Week High | $267.24 | $676.70 |
52-Week Low | $172.78 | $431.56 |
Enterprise Value | $654.37B | $154.71B |
Dividend Yield | 2.06% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Lockheed Martin (LMT) trades at $603.16, up 2.59% with strong technical momentum and bullish moving averages. The company reported mixed Q2 2026 earnings with a beat on EPS but faces margin pressure with net income margin declining to 8.16%. Recent news highlights major defense contracts including a $53.9 billion Patriot missile order and successful testing of next-generation interceptors, supporting the record $230 billion backlog.
Outlook remains positive with analyst consensus at Buy (56.76%) and $608 price target, though risks include execution on massive backlog and margin sustainability. The stock offers steady dividends ($3.45 quarterly) and benefits from elevated defense spending, but valuation multiples (P/E 22.04) require continued earnings growth to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
